ALPHAMAB ONCOLO.DL-000002 (3NK) — Capital Reinvestment Ratio
Latest as of December 2024:
0.10x
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Capital Reinvestment Ratio of 0.10x as of December 2024, meaning it reinvests 0% of its operating cash flow (€212.34 Million) in capital expenditures (€21.77 Million). See ALPHAMAB ONCOLO.DL-000002 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.10x
Capex / Operating Cash Flow
Operating Cash Flow
€212.34 Million
EUR
Capital Expenditures
€21.77 Million
EUR
Data as of
Dec 2024
Most recent filing
ALPHAMAB ONCOLO.DL-000002 Capital Reinvestment Ratio (2024–2024)
This chart tracks ALPHAMAB ONCOLO.DL-000002's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for ALPHAMAB ONCOLO.DL-000002 (2024–2024)
Year-by-year Capital Reinvestment Ratio for ALPHAMAB ONCOLO.DL-000002 from 2024 to 2024. For live market cap and broader valuation context, see 3NK market cap overview.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.10x | €212.34 Million | €21.77 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow